Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling

Blood

Volumn 119, Issue 8, 2012, Pages 1810-1820

  Hume, David A ^a   MacDonald, Kelli P A ^b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AFS 98; ANTINEOPLASTIC AGENT; COLONY STIMULATING FACTOR 1; COLONY STIMULATING FACTOR ANTIBODY; COLONY STIMULATING FACTOR RECEPTOR; CYTOKINE ANTIBODY; GW 2580; IMATINIB; KI 20227; RECOMBINANT COLONY STIMULATING FACTOR 1; UNCLASSIFIED DRUG;

ARTHRITIS; BONE MARROW TRANSPLANTATION; BONE METASTASIS; CELL MATURATION; CHRONIC MYELOID LEUKEMIA; DRUG DOSE INCREASE; DRUG EFFICACY; ENZYME INHIBITION; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; INFLAMMATORY DISEASE; INVASIVE CANDIDIASIS; MACROPHAGE; MELANOMA; MONOCYTE; NEUTROPENIA; NONHUMAN; OSTEOSARCOMA; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; TISSUE REPAIR;

EID: 84857618521     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-09-379214     Document Type: Review

References (144)

1. Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and functions. Immunity. 2010;32(5):593-604.
2. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol. 2005;5(12):953-964. (Pubitemid 41746764)
3. Hume DA. The mononuclear phagocyte system. Curr Opin Immunol. 2006;18(1):49-53. (Pubitemid 43049647)
4. Hume DA. Differentiation and heterogeneity in the mononuclear phagocyte system. Mucosal Immunol. 2008;1(6):432-441.
5. Hume DA, Ross IL, Himes SR, Sasmono RT, Wells CA, Ravasi T. The mononuclear phagocyte system revisited. J Leukoc Biol. 2002;72(4):621-627. (Pubitemid 36277831)
6. Pollard JW. Trophic macrophages in development and disease. Nat Rev Immunol. 2009;9(4): 259-270.
7. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon- gamma: an overview of signals, mechanisms and functions. J Leukoc Biol. 2004;75(2): 163-189. (Pubitemid 38174573)
8. Porta C, Rimoldi M, Raes G, et al. Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor kappaB. Proc Natl Acad Sci U S A. 2009; 106(35):14978-14983.
9. Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. Front Biosci. 2008;13:453-461. (Pubitemid 351599757)
10. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;11(10):889-896.
11. Mabbott NA, Kenneth Baillie J, Hume DA, Freeman TC. Meta-analysis of lineage-specific gene expression signatures in mouse leukocyte populations. Immunobiology. 2010;215(9):724-736.
12. Ravasi T, Wells C, Forest A, et al. Generation of diversity in the innate immune system: macrophage heterogeneity arises from gene-autonomous transcriptional probability of individual inducible genes. J Immunol. 2002;168(1):44-50. (Pubitemid 34014100)
13. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008;8(12):958-969.
14. Hume DA. Macrophages as APC and the dendritic cell myth. J Immunol. 2008;181(9):5829-5835.
15. Stanley ER, Cifone M, Heard PM, Defendi V. Factors regulating macrophage production and growth: identity of colony-stimulating factor and macrophage growth factor. J Exp Med. 1976; 143(3):631-647.
16. Breen FN, Hume DA, Weidemann MJ. Interactions among granulocyte- macrophage colony-stimulating factor, macrophage colony-stimulating factor, and IFN-gamma lead to enhanced proliferation of murine macrophage progenitor cells. J Immunol. 1991;147(5):1542-1547.
17. Breen FN, Hume DA, Weidemann MJ. The effects of interleukin 3 (IL-3) on cells responsive to macrophage colony-stimulating factor (CSF-1) in liquid murine bone marrow culture. Br J Haematol. 1990;74(2):138-145. (Pubitemid 20041086)
18. Caracciolo D, Shirsat N, Wong GG, Lange B, Clark S, Rovera G. Recombinant human macrophage colony-stimulating factor (M-CSF) requires subliminal concentrations of granulocyte/macrophage (GM)-CSF for optimal stimulation of human macrophage colony formation in vitro. J Exp Med. 1987;166(6):1851-1860. (Pubitemid 18000360)
19. Chitu V, Stanley ER. Colony-stimulating factor-1 in immunity and inflammation. Curr Opin Immunol. 2006;18(1):39-48. (Pubitemid 43049646)
20. Sweet MJ, Hume DA. CSF-1 as a regulator of macrophage activation and immune responses. Arch Immunol Ther Exp (Warsz). 2003;51(3):169-177. (Pubitemid 36828179)
21. Gow DJ, Sester DP, Hume DA. CSF-1, IGF-1, and the control of postnatal growth and development. J Leukoc Biol. 2010;88(3):475-481.
22. Lloyd SA, Yuan YY, Simske SJ, Riffle SE, Ferguson VL, Bateman TA. Administration of high-dose macrophage colony-stimulating factor increases bone turnover and trabecular volume fraction. J Bone Miner Metab. 2009;27(5):546-554.
23. Kawasaki ES, Ladner MB, Wang AM, et al. Molecular cloning of a complementary DNA encoding human macrophage-specific colony-stimulating factor (CSF-1). Science. 1985;230(4723):291-296. (Pubitemid 16225662)
24. .Wong GG, Temple PA, Leary AC, et al. Human CSF-1: molecular cloning and expression of 4-kb cDNA encoding the human urinary protein. Science. 1987;235(4795):1504-1508.
25. Pandit J, Bohm A, Jancarik J, Halenbeck R, Koths K, Kim SH. Three-dimensional structure of dimeric human recombinant macrophage colony-stimulating factor. Science. 1992;258(5086): 1358-1362. (Pubitemid 23007788)
26. Chen X, Liu H, Focia PJ, Shim AH, He X. Structure of macrophage colony stimulating factor bound to FMS: diverse signaling assemblies of class III receptor tyrosine kinases. Proc Natl Acad Sci U S A. 2008;105(47):18267-18272.
27. Lin H, Lee E, Hestir K, et al. Discovery of a cytokine and its receptor by functional screening of the extracellular proteome. Science. 2008; 320(5877):807-811. (Pubitemid 351929632)
28. Dai XM, Ryan GR, Hapel AJ, et al. Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects. Blood. 2002;99(1):111-120.
29. .Wei S, Nandi S, Chitu V, et al. Functional overlap but differential expression of CSF-1 and IL-34 in their CSF-1 receptor-mediated regulation of myeloid cells. J Leukoc Biol. 2010;88(3):495-505.
30. Garceau V, Smith J, Paton IR, et al. Pivotal advance: avian colony-stimulating factor 1 (CSF-1), interleukin-34 (IL-34), and CSF-1 receptor genes and gene products. J Leukoc Biol. 2010;87(5): 753-764.
31. Chihara T, Suzu S, Hassan R, et al. IL-34 and M-CSF share the receptor Fms but are not identical in biological activity and signal activation. Cell Death Differ. 2010;17(12):1917-1927.
32. Eda H, Zhang J, Keith RH, Michener M, Beidler DR, Monahan JB. Macrophage-colony stimulating factor and interleukin-34 induce chemokines in human whole blood. Cytokine. 2010;52(3):215-220.
33. Bonifer C, Hume DA. The transcriptional regulation of the colony-stimulating factor 1 receptor (csf1r) gene during hematopoiesis. Front Biosci. 2008;13:549-560. (Pubitemid 351599765)
34. Ovchinnikov DA, DeBats CE, Sester DP, Sweet MJ, Hume DA. A conserved distal segment of the mouse CSF-1 receptor promoter is required for maximal expression of a reporter gene in macrophages and osteoclasts of transgenic mice. J Leukoc Biol. 2010;87(5):815-822.
35. Sasmono RT, Oceandy D, Pollard JW, et al. A macrophage colony-stimulating factor receptor-green fluorescent protein transgene is expressed throughout the mononuclear phagocyte system of the mouse. Blood. 2003;101(3):1155-1163. (Pubitemid 36139391)
36. Hume DA, Pavli P, Donahue RE, Fidler IJ. The effect of human recombinant macrophage colony-stimulating factor (CSF-1) on the murine mononuclear phagocyte system in vivo. J Immunol. 1988; 141(10):3405-3409.
37. Ulich TR, del Castillo J, Watson LR, Yin SM, Garnick MB. In vivo hematologic effects of recombinant human macrophage colony-stimulating factor. Blood. 1990;75(4):846-850. (Pubitemid 20067181)
38. Munn DH, Garnick MB, Cheung NK. Effects of parenteral recombinant human macrophage colony-stimulating factor on monocyte number, phenotype, and antitumor cytotoxicity in nonhuman primates. Blood. 1990;75(10):2042-2048. (Pubitemid 20180295)
39. VandePol CJ, Garnick MB. Clinical applications of recombinant macrophage-colony stimulating factor (rhM-CSF). Biotechnol Ther. 1991;2(3):231-239.
40. Hamilton JA. Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol. 2008;8(7):533-544. (Pubitemid 351913679)
41. Pollard JW, Bartocci A, Arceci R, Orlofsky A, Ladner MB, Stanley ER. Apparent role of the macrophage growth factor, CSF-1, in placental development. Nature. 1987;330(6147):484-486. (Pubitemid 18006429)
42. Bartocci A, Pollard JW, Stanley ER. Regulation of colony-stimulating factor 1 during pregnancy. J Exp Med. 1986;164(3):956-961. (Pubitemid 16024849)
43. Roth P, Stanley ER. Colony stimulating factor-1 expression is developmentally regulated in the mouse. J Leukoc Biol. 1996;59(6):817-823. (Pubitemid 26238477)
44. Roth P, Stanley ER. Colony-stimulating factor-1 expression in the human fetus and newborn. J Leukoc Biol. 1995;58(4):432-437.
45. Irvine KM, Burns CJ, Wilks AF, Su S, Hume DA, Sweet MJ.ACSF-1 receptor kinase inhibitor targets effector functions and inhibits pro-inflammatory cytokine production from murine macrophage populations. FASEB J. 2006;20(11):1921-1923.
46. Williams GT, Smith CA, Spooncer E, Dexter TM, Taylor DR. Haemopoietic colony stimulating factors promote cell survival by suppressing apoptosis. Nature. 1990;343(6253):76-79.
47. Bartocci A, Mastrogiannis DS, Migliorati G, Stockert RJ, Wolkoff AW, Stanley ER. Macrophages specifically regulate the concentration of their own growth factor in the circulation. Proc Natl Acad Sci U S A. 1987;84(17):6179- 6183.
48. Irvine KM, Andrews MR, Fernandez-Rojo MA, et al. Colony-stimulating factor-1 (CSF-1) delivers a proatherogenic signal to human macrophages. J Leukoc Biol. 2009;85(2):278-288.
49. Martinez FO, Gordon S, Locati M, Mantovani A. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol. 2006;177(10):7303-7311. (Pubitemid 44715100)
50. Randolph GJ, Jakubzick C, Qu C. Antigen presentation by monocytes and monocyte-derived cells. Curr Opin Immunol. 2008;20(1):52-60.
51. Svensson J, Jenmalm MC, Matussek A, Geffers R, Berg G, Ernerudh J. Macrophages at the fetal-maternal interface express markers of alternative activation and are induced by M-CSF and IL-10. J Immunol. 2011;187(7):3671-3682.
52. Rehli M, Sulzbacher S, Pape S, et al. Transcription factor Tfec contributes to the IL-4-inducible expression of a small group of genes in mouse macrophages including the granulocyte colony-stimulating factor receptor. J Immunol. 2005; 174(11):7111-7122. (Pubitemid 40705677)
53. Stacey KJ, Fowles LF, Colman MS, Ostrowski MC, Hume DA. Regulation of urokinase-type plasminogen activator gene transcription by macrophage colony-stimulating factor. Mol Cell Biol. 1995; 15(6):3430-3441.
54. Hamilton JA, Whitty GA, Stanton H, et al. Macrophage colony-stimulating factor and granulocyte-macrophage colony-stimulating factor stimulate the synthesis of plasminogen-activator inhibitors by human monocytes. Blood. 1993;82(12):3616-3621. (Pubitemid 24006042)
55. Fowles LF, Martin ML, Nelsen L, et al. Persistent activation of mitogen-activated protein kinases p42 and p44 and ets-2 phosphorylation in response to colony-stimulating factor 1/c-fms signaling. Mol Cell Biol. 1998;18(9):5148-5156. (Pubitemid 28388098)
56. Zhao B, Li Y, Buono C, et al. Constitutive receptor-independent low density lipoprotein uptake and cholesterol accumulation by macrophages differentiated from human monocytes with macrophage-colony-stimulating factor (M-CSF). J Biol Chem. 2006;281(23):15757-15762. (Pubitemid 43848465)
57. .Wall MJ, Chen J, Meegalla S, et al. Synthesis and evaluation of novel 3,4,6-substituted 2-quinolones as FMS kinase inhibitors. Bioorg Med Chem Lett. 2008; 18(6):2097-2102. (Pubitemid 351391842)
58. Tushinski RJ, Stanley ER. The regulation of mononuclear phagocyte entry into S phase by the colony stimulating factor CSF-1. J Cell Physiol. 1985;122(2):221-228. (Pubitemid 15164123)
59. Bauer RJ, Gibbons JA, Bell DP, Luo ZP, Young JD. Nonlinear pharmacokinetics of recombinant human macrophage colony-stimulating factor (M-CSF) in rats. J Pharmacol Exp Ther. 1994;268(1):152-158. (Pubitemid 24039082)
60. Fancke B, Suter M, Hochrein H, O'Keeffe M. M-CSF: a novel plasmacytoid and conventional dendritic cell poietin. Blood. 2008;111(1):150-159.
61. MacDonald KP, Rowe V, Bofinger HM, et al. The colony-stimulating factor 1 receptor is expressed on dendritic cells during differentiation and regulates their expansion. J Immunol. 2005;175(3): 1399-1405. (Pubitemid 41023039)
62. Auffray C, Fogg DK, Narni-Mancinelli E, et al. CX3CR1+ CD115+ CD135+ common macrophage/DC precursors and the role of CX3CR1 in their response to inflammation. J Exp Med. 2009; 206(3):595-606.
63. Stoudemire JB, Garnick MB. Effects of recombinant human macrophage colony-stimulating factor on plasma cholesterol levels. Blood. 1991; 77(4):750-755.
64. Geissmann F, Auffray C, Palframan R, et al. Blood monocytes: distinct subsets, how they relate to dendritic cells, and their possible roles in the regulation of T-cell responses. Immunol Cell Biol. 2008;86(5):398-408. (Pubitemid 351948210)
65. Ziegler-Heitbrock L, Ancuta P, Crowe S, et al. Nomenclature of monocytes and dendritic cells in blood. Blood. 2010;116(16):e74-e80.
66. Ingersoll MA, Spanbroek R, Lottaz C, et al. Comparison of gene expression profiles between human and mouse monocyte subsets. Blood. 2010; 115(3):e10-e19.
67. Geissmann F, Jung S, Littman DR. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity. 2003;19(1):71-82. (Pubitemid 36859902)
68. Auffray C, Fogg D, Garfa M, et al. Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science. 2007;317(5838):666-670. (Pubitemid 47229966)
69. MacDonald KP, Palmer JS, Cronau S, et al. An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but does not inhibit inflammation. Blood. 2010;116(19):3955-3963.
70. Heuser M, Ganser A, Bokemeyer C. Use of colony-stimulating factors for chemotherapy-associated neutropenia: review of current guidelines. Semin Hematol. 2007;44(3):148-156. (Pubitemid 47031224)
71. Masaoka T, Shibata H, Ohno R, et al. Double-blind test of human urinary macrophage colony-stimulating factor for allogeneic and syngeneic bone marrow transplantation: effectiveness of treatment and 2-year follow-up for relapse of leukaemia. Br J Haematol. 1990;76(4):501-505.
72. Hidaka T, Akada S, Teranishi A, et al. Mirimostim (macrophage colony-stimulating factor; M-CSF) improves chemotherapy-induced impaired natural killer cell activity, Th1/Th2 balance, and granulocyte function. Cancer Sci. 2003;94(9):814-820. (Pubitemid 37258781)
73. Cole DJ, Sanda MG, Yang JC, et al. Phase I trial of recombinant human macrophage colony-stimulating factor administered by continuous intravenous infusion in patients with metastatic cancer. J Natl Cancer Inst. 1994;86(1):39-45. (Pubitemid 24018382)
74. Jakubowski AA, Bajorin DF, Templeton MA, et al. Phase I study of continuous-infusion recombinant macrophage colony-stimulating factor in patients with metastatic melanoma. Clin Cancer Res. 1996;2(2):295-302. (Pubitemid 26074617)
75. Hume DA, Donahue RE, Fidler IJ. The therapeutic effect of human recombinant macrophage colony stimulating factor (CSF-1) in experimental murine metastatic melanoma. Lymphokine Res. 1989;8(1):69-77. (Pubitemid 19075260)
76. Bukowski RM, Budd GT, Gibbons JA, et al. Phase I trial of subcutaneous recombinant macrophage colony-stimulating factor: clinical and immuno-modulatory effects. J Clin Oncol. 1994;12(1):97-106.
77. Cenci E, Bartocci A, Puccetti P, Mocci S, Stanley ER, Bistoni F. Macrophage colony-stimulating factor in murine candidiasis: serum and tissue levels during infection and protective effect of exogenous administration. Infect Immun. 1991;59(3):868-872.
78. Nemunaitis J, Shannon-Dorcy K, Appelbaum FR, et al. Long-term follow-up of patients with invasive fungal disease who received adjunctive therapy with recombinant human macrophage colony-stimulating factor. Blood. 1993;82(5): 1422-1427. (Pubitemid 23263957)
79. Abd AH, Savage NW, Halliday WJ, Hume DA. The role of macrophages in experimental arthritis induced by Streptococcus agalactiae sonicate: actions of macrophage colony-stimulating factor (CSF-1) and other macrophage-modulating agents. Lymphokine Cytokine Res. 1991;10(1): 43-50.
80. Han Y, Ma FY, Tesch GH, Manthey CL, Nikolic-Paterson DJ. c-fms blockade reverses glomerular macrophage infiltration and halts development of crescentic anti-GBM glomerulonephritis in the rat. Lab Invest. 2011;91:978-991.
81. Jose MD, Ikezumi Y, van Rooijen N, Atkins RC, Chadban SJ. Macrophages act as effectors of tissue damage in acute renal allograft rejection. Transplantation. 2003;76(7):1015-1022. (Pubitemid 37280827)
82. Menke J, Rabacal WA, Byrne KT, et al. Circulating CSF-1 promotes monocyte and macrophage phenotypes that enhance lupus nephritis. J Am Soc Nephrol. 2009;20(12):2581-2592.
83. Jose MD, Le Meur Y, Atkins RC, Chadban SJ. Blockade of macrophage colony-stimulating factor reduces macrophage proliferation and accumulation in renal allograft rejection. Am J Transplant. 2003;3(3):294-300. (Pubitemid 36407047)
84. Hume DA, Denkins Y. The deleterious effect of macrophage colony-stimulating factor (CSF-1) on the pathology of experimental candidiasis in mice. Lymphokine Cytokine Res. 1992;11(2):95-98.
85. Shin EK, Lee SH, Cho SH, et al. Association between colony-stimulating factor 1 receptor gene polymorphisms and asthma risk. Hum Genet. 2010;128(3):293-302.
86. Albagha OM, Visconti MR, Alonso N, et al. Genome-wide association study identifies variants at CSF1, OPTN and TNFRSF11A as genetic risk factors for Paget's disease of bone. Nat Genet. 2010;42(6):520-524.
87. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol. 2003;21:685-711. (Pubitemid 37174545)
88. Lin HH, Faunce DE, Stacey M, et al. The macrophage F4/80 receptor is required for the induction of antigen-specific efferent regulatory T cells in peripheral tolerance. J Exp Med. 2005;201(10): 1615-1625. (Pubitemid 40721005)
89. Manrique SZ, Duque Correa MA, Hoelzinger DB, et al. Foxp3-positive macrophages display immunosuppressive properties and promote tumor growth. J Exp Med. 2011;208(7):1485-1499.
90. Doyle AG, Halliday WJ, Barnett CJ, Dunn TL, Hume DA. Effect of recombinant human macrophage colony-stimulating factor 1 on immunopathology of experimental brucellosis in mice. Infect Immun. 1992;60(4):1465-1472.
91. Sakurai T, Yamada M, Simamura S, Motoyoshi K. Recombinant human macrophage-colony stimulating factor suppresses the mouse mixed lymphocyte reaction. Cell Immunol. 1996;171(1):87-94. (Pubitemid 26349129)
92. Sakurai T,Wakimoto N, Yamada M, Shimamura S, Motoyoshi K. Effect of macrophage colony-stimulating factor (M-CSF) on mouse immune responses in vivo. Immunopharmacol Immunotoxicol. 1998;20(1):79-102. (Pubitemid 28157292)
93. Praloran V, Raventos-Suarez C, Bartocci A, Lucas J, Stanley ER, Gibbons JJ Jr. Alterations in the expression of colony-stimulating factor-1 and its receptor during an acute graft-vs-host reaction in mice. J Immunol. 1990;145(10):3256-3261.
94. Blazar BR, Aukerman SL, Vallera DA. Effect of recombinant human macrophage colony-stimulating factor in irradiated murine recipients of T-cell-depleted allogeneic or non-depleted syngeneic bone marrow transplants. Blood. 1992; 79(6):1636-1642.
95. Sakurai T, Misawa E, Yamada M, Hayasawa H, Motoyoshi K. Comparative study and effects of macrophage colony-stimulating factor (M-CSF) administration on NK1.1+ cells in mouse spleen and bone marrow. Immunopharmacol Immunotoxicol. 2002;24(4):547-566. (Pubitemid 36008316)
96. Hashimoto D, Chow A, Greter M, et al. Pretransplant CSF-1 therapy expands recipient macrophages and ameliorates GVHD after allogeneic hematopoietic cell transplantation. J Exp Med. 2011;208(5):1069-1082.
97. Kimura F, Sato K, Akiyama H, et al. M-CSF attenuates severity of chronic GVHD after unrelated BMT [published online ahead of print April 18, 2011]. Bone Marrow Transplant. doi:10.1038/bmt.2011.90.
98. Nemunaitis J, Meyers JD, Buckner CD, et al. Phase I trial of recombinant human macrophage colony-stimulating factor in patients with invasive fungal infections. Blood. 1991;78(4):907-913.
99. Nishimura K, Tanaka N, Ohshige A, Fukumatsu Y, Matsuura K, Okamura H. Effects of macrophage colony-stimulating factor on folliculogenesis in gonadotrophin-primed immature rats. J Reprod Fertil. 1995;104(2):325-330.
100. Nishimura K, Tanaka N, Kawano T, Matsuura K, Okamura H. Changes in macrophage colony-stimulating factor concentration in serum and follicular fluid in in-vitro fertilization and embryo transfer cycles. Fertil Steril. 1998;69(1):53-57. (Pubitemid 28072991)
101. Takasaki A, Ohba T, Okamura Y, et al. Clinical use of colony-stimulating factor-1 in ovulation induction for poor responders. Fertil Steril. 2008; 90(6):2287-2290.
102. Jenkins SJ, Ruckerl D, Cook PC, et al. Local macrophage proliferation, rather than recruitment from the blood, is a signature of TH2 inflammation. Science. 2011;332(6035):1284-1288.
103. Alexander KA, Chang MK, Maylin ER, et al. Osteal macrophages promote in vivo intramembranous bone healing in a mouse tibial injury model. J Bone Miner Res. 2011;26(7):1517-1532.
104. Alikhan MA, Jones CV, Williams TM, et al. Colony-stimulating factor-1 promotes kidney growth and repair via alteration of macrophage responses. Am J Pathol. 2011;179(3):1243-1256.
105. Menke J, Iwata Y, Rabacal WA, et al. CSF-1 signals directly to renal tubular epithelial cells to mediate repair in mice. J Clin Invest. 2009;119(8): 2330-2342.
106. Okazaki T, Ebihara S, Asada M, et al. Macrophage colony-stimulating factor improves cardiac function after ischemic injury by inducing vascular endothelial growth factor production and survival of cardiomyocytes. Am J Pathol. 2007;171(4): 1093-1103. (Pubitemid 47582885)
107. Okuno Y, Nakamura-Ishizu A, Kishi K, Suda T, Kubota Y. Bone marrow-derived cells serve as proangiogenic macrophages but not endothelial cells in wound healing. Blood. 2011;117(19): 5264-5272.
108. Boissonneault V, Filali M, Lessard M, Relton J, Wong G, Rivest S. Powerful beneficial effects of macrophage colony-stimulating factor on beta-amyloid deposition and cognitive impairment in Alzheimer's disease. Brain. 2009;132(4):1078-1092.
109. Mitrasinovic OM, Vincent VA, Simsek D, Murphy GM Jr. Macrophage colony stimulating factor promotes phagocytosis by murine microglia. Neurosci Lett. 2003;344(3):185-188. (Pubitemid 36694674)
110. Mooney JE, Rolfe BE, Osborne GW, et al. Cellular plasticity of inflammatory myeloid cells in the peritoneal foreign body response. Am J Pathol. 2010;176(1):369-380.
111. Hume DA, Gordon S. Mononuclear phagocyte system of the mouse defined by immunohistochemical localization of antigen F4/80: identification of resident macrophages in renal medullary and cortical interstitium and the juxtaglomerular complex. J Exp Med. 1983;157(5):1704-1709. (Pubitemid 13089010)
112. Chang MK, Raggatt LJ, Alexander KA, et al. Osteal tissue macrophages are intercalated throughout human and mouse bone lining tissues and regulate osteoblast function in vitro and in vivo. J Immunol. 2008;181(2):1232-1244.
113. Rae F, Woods K, Sasmono T, et al. Characterisation and trophic functions of murine embryonic macrophages based upon the use of a Csf1r-EGFP transgene reporter. Dev Biol. 2007;308(1): 232-246. (Pubitemid 47087792)
114. Burns CJ, Wilks AF. c-FMS inhibitors: a patent review. Expert Opin Ther Pat. 2011;21(2):147-165.
115. Conway JG, McDonald B, Parham J, et al. Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580. Proc Natl Acad Sci U S A. 2005; 102(44):16078-16083. (Pubitemid 41552870)
116. Hume DA. Applications of myeloid-specific promoters in transgenic mice support in vivo imaging and functional genomics but do not support the concept of distinct macrophage and dendritic cell lineages or roles in immunity. J Leukoc Biol. 2011; 89(4):525-538.
117. Wei S, Lightwood D, Ladyman H, et al. Modulation of CSF-1-regulated post-natal development with anti-CSF-1 antibody. Immunobiology. 2005; 210(2):109-119. (Pubitemid 41025151)
118. Lokeshwar BL, Lin HS. Development and characterization of monoclonal antibodies to murine macrophage colony-stimulating factor. J Immunol. 1988;141(2):483-488.
119. Campbell IK, Rich MJ, Bischof RJ, Hamilton JA. The colony-stimulating factors and collagen-induced arthritis: exacerbation of disease by M-CSF and G-CSF and requirement for endogenous M-CSF. J Leukoc Biol. 2000;68(1):144-150.
120. Cenci S, Weitzmann MN, Gentile MA, Aisa MC, Pacifici R. M-CSF neutralization and egr-1 deficiency prevent ovariectomy-induced bone loss. J Clin Invest. 2000;105(9):1279-1287. (Pubitemid 30266081)
121. Radi ZA, Koza-Taylor PH, Bell RR, et al. Increased serum enzyme levels associated with kupffer cell reduction with no signs of hepatic or skeletal muscle injury. Am J Pathol. 2011;179(1): 240-247.
122. Sudo T, Nishikawa S, Ogawa M, et al. Functional hierarchy of c-kit and c-fms in intramarrow production of CFU-M. Oncogene. 1995;11(12):2469-2479.
123. Murayama T, Yokode M, Kataoka H, et al. Intraperitoneal administration of anti-c-fms monoclonal antibody prevents initial events of atherogenesis but does not reduce the size of advanced lesions in apolipoprotein E-deficient mice. Circulation. 1999;99(13):1740-1746. (Pubitemid 29162488)
124. LimAK,Ma FY, Nikolic-Paterson DJ, Thomas MC, Hurst LA, Tesch GH. Antibody blockade of c-fms suppresses the progression of inflammation and injury in early diabetic nephropathy in obese db/db mice. Diabetologia. 2009;52(8):1669-1679.
125. Segawa M, Fukada S, Yamamoto Y, et al. Suppression of macrophage functions impairs skeletal muscle regeneration with severe fibrosis. Exp Cell Res. 2008;314(17):3232-3244.
126. Kubota Y, Takubo K, Shimizu T, et al. M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis. J Exp Med. 2009; 206(5):1089-1102.
127. Lenzo JC, Turner AL, Cook AD, et al. Control of macrophage lineage populations by CSF-1 receptor and GM-CSF in homeostasis and inflammation [published online ahead of print July15, 2011]. Immunol Cell Biol. doi:10.1038/icb.2011.58.
128. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell. 2006;124(2):263-266. (Pubitemid 43121975)
129. .Wyckoff JB, Wang Y, Lin EY, et al. Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res. 2007; 67(6):2649-2656. (Pubitemid 46548952)
130. Tagliani E, Shi C, Nancy P, Tay CS, Pamer EG, Erlebacher A. Coordinate regulation of tissue macrophage and dendritic cell population dynamics by CSF-1. J Exp Med. 2011;208(9):1901-1916.
131. Pollard JW, Hunt JS, Wiktor-Jedrzejczak W, Stanley ER. A pregnancy defect in the osteopetrotic (op/op) mouse demonstrates the requirement for CSF-1 in female fertility. Dev Biol. 1991; 148(1):273-283. (Pubitemid 121004766)
132. Winkler IG, Sims NA, Pettit AR, et al. Bone marrow macrophages maintain hematopoietic stem cell (HSC) niches and their depletion mobilizes HSCs. Blood. 2010;116(23):4815-4828.
133. Ober RJ, Radu CG, Ghetie V, Ward ES. Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int Immunol. 2001;13(12):1551-1559. (Pubitemid 33133882)
134. Unkeless JC, Scigliano E, Freedman VH. Structure and function of human and murine receptors for IgG. Annu Rev Immunol. 1988;6:251-281. (Pubitemid 19141584)
135. Conway JG, Pink H, Bergquist ML, et al. Effects of the cFMS kinase inhibitor 5-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine (GW2580) in normal and arthritic rats. J Pharmacol Exp Ther. 2008;326(1):41-50. (Pubitemid 351872132)
136. Priceman SJ, Sung JL, Shaposhnik Z, et al. Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. Blood. 2010; 115(7):1461-1471.
137. Ohno H, Uemura Y, Murooka H, et al. The orally-active and selective c-Fms tyrosine kinase inhibitor Ki20227 inhibits disease progression in a collagen-induced arthritis mouse model. Eur J Immunol. 2008;38(1):283-291.
138. Uemura Y, Ohno H, Ohzeki Y, et al. The selective M-CSF receptor tyrosine kinase inhibitor Ki20227 suppresses experimental autoimmune encephalomyelitis. J Neuroimmunol. 2008;195(1):73-80.
139. Manthey CL, Johnson DL, Illig CR, et al. JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia. Mol Cancer Ther. 2009; 8(11):3151-3161.
140. Dewar AL, Cambareri AC, Zannettino AC, et al. Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood. 2005; 105(8):3127-3132.
141. Paniagua RT, Chang A, Mariano MM, et al. c-Fms-mediated differentiation and priming of monocyte lineage cells play a central role in autoimmune arthritis. Arthritis Res Ther. 2010;12(1):R32.
142. Fairbairn L, Kapetanovic R, Sester DP, Hume DA. The mononuclear phagocyte system of the pig as a model for understanding human innate immunity and disease. J Leukoc Biol. 2011;89(6):855-871.
143. Nowicki A, Szenajch J, Ostrowska G, et al. Impaired tumor growth in colony-stimulating factor 1 (CSF-1)-deficient, macrophage-deficient op/op mouse: evidence for a role of CSF-1-dependent macrophages in formation of tumor stroma. Int J Cancer. 1996;65(1):112-119. (Pubitemid 26030942)
144. Amemiya H, Kono H, Fujii H. Liver regeneration is impaired in macrophage colony stimulating factor deficient mice after partial hepatectomy: the role of M-CSF-induced macrophages. J Surg Res. 2011;165(1):59-67.